Award
National Cancer Institute 4UH3CA283652-03
Next generation T cell therapies for mutant KRAS solid tumors
Recipient
University of Pennsylvania
Award Amount
$2,238,704.00
Ceiling
$2,238,704.00
Awarded
September 19, 2025
Identifier
4UH3CA283652-03
Award for developing advanced T cell therapies targeting mutant KRAS in solid tumors, including clinical trials and gene editing, managed by the National Cancer Institute with a budget of approximately $2.24 million.
Description
This project aims to develop the next generation of T cell therapies targeting mutant KRAS in adult solid tumors. It involves early-stage clinical testing of TCR1020, a T cell receptor specific for mKRAS G12V restricted to HLA-A*11:01, to treat approximately 5,000 new adult cancer patients annually in the US. The project includes gene editing technologies, overcoming tumor microenvironment resistance, and a multi-site phase 1 clinical trial. The award is managed by the National Cancer Institute and involves multiple investigators and institutions including the University of Pennsylvania.